These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 37406430

  • 1. Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.
    Nose Y, Fujii H, Goto S, Kono K, Okamoto H, Watanabe K, Nishi S.
    Mol Genet Metab; 2023 Aug; 139(4):107634. PubMed ID: 37406430
    [Abstract] [Full Text] [Related]

  • 2. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
    Liu HC, Lin HY, Yang CF, Liao HC, Hsu TR, Lo CW, Chang FP, Huang CK, Lu YH, Lin SP, Yu WC, Niu DM.
    Orphanet J Rare Dis; 2014 Jul 22; 9():111. PubMed ID: 25047006
    [Abstract] [Full Text] [Related]

  • 3. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
    Togawa T, Kawashima I, Kodama T, Tsukimura T, Suzuki T, Fukushige T, Kanekura T, Sakuraba H.
    Biochem Biophys Res Commun; 2010 Sep 03; 399(4):716-20. PubMed ID: 20692233
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K, Yamamoto H.
    BMC Pharmacol Toxicol; 2017 Jun 07; 18(1):43. PubMed ID: 28592315
    [Abstract] [Full Text] [Related]

  • 5. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
    Sakuraba H, Togawa T, Tsukimura T, Kato H.
    Clin Exp Nephrol; 2018 Aug 07; 22(4):843-849. PubMed ID: 29288396
    [Abstract] [Full Text] [Related]

  • 6. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H.
    Mol Genet Metab; 2010 Jul 07; 100(3):257-61. PubMed ID: 20409739
    [Abstract] [Full Text] [Related]

  • 7. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
    Talbot A, Nicholls K, Fletcher JM, Fuller M.
    Mol Genet Metab; 2017 Sep 07; 122(1-2):121-125. PubMed ID: 28847675
    [Abstract] [Full Text] [Related]

  • 8. Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease.
    Alharbi FJ, Baig S, Auray-Blais C, Boutin M, Ward DG, Wheeldon N, Steed R, Dawson C, Hughes D, Geberhiwot T.
    J Inherit Metab Dis; 2018 Mar 07; 41(2):239-247. PubMed ID: 29294190
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort.
    Effraimidis G, Feldt-Rasmussen U, Rasmussen ÅK, Lavoie P, Abaoui M, Boutin M, Auray-Blais C.
    J Med Genet; 2021 Oct 07; 58(10):692-700. PubMed ID: 32963035
    [Abstract] [Full Text] [Related]

  • 11. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
    Shima H, Tsukimura T, Shiga T, Togawa T, Sakuraba H, Doi T, Ikeda Y, Okamoto T, Yoshikawa Y, Kimura T, Iwase T, Inoue T, Tashiro M, Okada K, Minakuchi J.
    CEN Case Rep; 2024 Aug 07; 13(4):290-296. PubMed ID: 38135868
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
    Boutin M, Auray-Blais C.
    Anal Chem; 2014 Apr 01; 86(7):3476-83. PubMed ID: 24634980
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
    Boutin M, Lavoie P, Menkovic I, Toupin A, Abaoui M, Elidrissi-Elawad M, Arthus MF, Fortier C, Ménard C, Maranda B, Bichet DG, Auray-Blais C.
    Int J Mol Sci; 2020 Aug 25; 21(17):. PubMed ID: 32854306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.